Moderna Inc. and Merck announced that the mRNA‑4157 vaccine, combined with KEYTRUDA, achieved a 49% reduction in recurrence or death among high‑risk melanoma patients in a pre‑planned analysis of the KEYNOTE‑942/mRNA‑4157‑P201 study. The hazard ratio of 0.51 (95% CI 0.29‑0.89) was based on 157 patients with a median follow‑up of five years, confirming durable benefit beyond the two‑ and three‑year checkpoints.
The five‑year data demonstrate that the personalized neoantigen vaccine can sustain clinical advantage over KEYTRUDA monotherapy, a milestone that could support a regulatory submission and eventual approval for adjuvant melanoma therapy. The sustained benefit is particularly noteworthy because it extends the window of protection in a disease where recurrence after surgery remains a major challenge.
Moderna’s oncology results arrive as the company’s COVID‑19 vaccine revenue has fallen 52.8% to $3.2 billion in 2024, prompting aggressive cost‑cutting and a focus on high‑margin mRNA medicines. The oncology platform, now generating a growing share of the company’s pipeline, is positioned to offset the decline in legacy vaccine sales and move the company toward cash‑break even by 2028. The five‑year data strengthen the case for a broader oncology portfolio that could deliver higher margins than the current vaccine business.
The personalized cancer vaccine market was valued at $208 million in 2024 and is projected to grow at a 44.9% CAGR through 2030. Moderna’s mRNA‑4157, as one of the first long‑term evidence‑based candidates, could capture a significant portion of this expanding market, reinforcing the company’s strategic pivot to diversified mRNA therapeutics.
Beyond melanoma, Moderna is advancing Phase 3 trials of mRNA‑4157 in non‑small cell lung cancer, bladder cancer, and renal cell carcinoma. The partnership with Merck, which supplies KEYTRUDA, provides a proven checkpoint inhibitor backbone that may accelerate regulatory review and market adoption. The company’s leadership views the five‑year data as a key milestone in its broader oncology strategy.
"The sustained benefit we see at five years confirms the promise of personalized mRNA vaccines and strengthens our confidence in the platform’s ability to deliver durable protection for patients," said Kyle Holen, Senior Vice President and Head of Development, Oncology and Therapeutics at Moderna. "These results reinforce our commitment to advancing the pipeline and moving toward regulatory approval in multiple indications.”
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.